Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery
NCT06998732Completed
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of remimazolam, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: 95% Effective Dose at 10 months. Started Jun 2025; status: completed.
02
Drugs
remimazolam
Beyond the preview
Go deeper on NCT06998732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998732.